Barclays on Collegium Pharmaceutical (COLL): 'we would add to positions at this level'

March 19, 2026 12:45 PM

Barclays analyst Glen Santangelo reiterated an Overweight rating and $56.00 price target on Collegium Pharmaceutical (NASDAQ: COLL)The analyst commented, "Coming ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found